Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Month: June 2026

1238-OR: Pioglitazone Prevents the Blunted Counterregulatory Response Induced by Recurrent Hypoglycemia

June 12, 2026 by sugaradmin

Introduction and Objective: Recurrent iatrogenic hypoglycemia blunts the counterregulatory response (CRR) to hypoglycemia. This study tested the hypothesis that RH induces insulin resistance and that the insulin sensitizer, pioglitazone, prevents the development of insulin resistance and consequently prevents the development of a blunted epinephrine response to hypoglycemia.Methods: 8-10-week-old rats were randomized to 1 of 3 […]

Read More
DiabetesLeave a Comment on 1238-OR: Pioglitazone Prevents the Blunted Counterregulatory Response Induced by Recurrent Hypoglycemia

1258-OR: Performance of a Next-Generation Algorithm for Omnipod in Adults with Type 2 Diabetes: Findings from the STRIVE Randomized Trial

June 12, 2026 by sugaradmin

Introduction and Objective: A recent randomized crossover trial compared a next-generation algorithm for Omnipod (Omnipod 6) with the first-generation Omnipod® 5 Automated Insulin Delivery System in a diverse population of adults (T1D/T2D) and children (T1D). Assessing performance of Omnipod 6 in those with T2D is needed given the unique pathophysiology, insulin needs, and concomitant therapy […]

Read More
DiabetesLeave a Comment on 1258-OR: Performance of a Next-Generation Algorithm for Omnipod in Adults with Type 2 Diabetes: Findings from the STRIVE Randomized Trial

1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial

June 12, 2026 by sugaradmin

Introduction and Objective: To evaluate the efficacy and safety of mazdutide (MAZ) 9 mg, a once-weekly GLP-1 and glucagon receptor dual agonist, in Chinese adults with obesity.Methods: In this randomized, double-blind, placebo (PBO)-controlled trial (NCT06164873, GLORY-2), 462 Chinese adults with obesity (BMI ≥30 kg/m2; 16.0% with T2D) were randomized in a 2:1 ratio to receive […]

Read More
DiabetesLeave a Comment on 1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial

1237-OR: A Novel Hypoglycemic Clamp Procedure to Assess “Spontaneous Time to Recovery” as a Clinically Relevant Safety Endpoint

June 12, 2026 by sugaradmin

Introduction and Objective: The conventional hypoglycemic clamp utilizes high-dose IV insulin at fixed rates to induce target hypoglycemia, lacks standardized protocols and results in insulin overdose affecting spontaneous recovery. This improved hypoglycemic clamp procedure adjusts for individual insulin sensitivity and assesses “time to spontaneous recovery” as a critical endpoint.Methods: 12 healthy (41±12 yrs, 28±2 kg/m2) […]

Read More
DiabetesLeave a Comment on 1237-OR: A Novel Hypoglycemic Clamp Procedure to Assess “Spontaneous Time to Recovery” as a Clinically Relevant Safety Endpoint

1270-OR: Differential Sorting of Immunomodulatory Islet Extracellular Vesicle Cargo Tracks with Heterogeneity in Beta-Cell Survival in Type 1 Diabetes

June 12, 2026 by sugaradmin

Introduction and Objective: We have shown that beta cell-derived extracellular vesicle (EV) programmed death ligand-1 (PD-L1) reduces CD8+ T-cell activity and may protect against beta cell killing in T1D. However, underlying mechanisms linking differences in islet EV cargo to heterogeneity in beta cell survival are poorly defined.Methods: EVs were isolated using size exclusion chromatography from […]

Read More
DiabetesLeave a Comment on 1270-OR: Differential Sorting of Immunomodulatory Islet Extracellular Vesicle Cargo Tracks with Heterogeneity in Beta-Cell Survival in Type 1 Diabetes

1253-OR: ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5

June 12, 2026 by sugaradmin

Introduction and Objective: The efficacy and safety of the daily oral, non-peptide GLP-1RA orforglipron (OFG) were assessed as add-on to insulin glargine with/without metformin and/or SGLT-2 inhibitors in adults with type 2 diabetes (T2D) (ACHIEVE-5; NCT06109311).Methods: In this 40-week double-blind, randomized, placebo-controlled, phase 3 study, participants with T2D and inadequate glycemic control were randomized (1:1:1:1) […]

Read More
DiabetesLeave a Comment on 1253-OR: ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5

1275-OR: Central Regulation of Glucose Production Is Affected by Insulin Levels

June 12, 2026 by sugaradmin

Introduction and Objective: Central KATP channel activation with diazoxide (DZX) suppresses endogenous glucose production (EGP) in rodents and humans (JCI 121:4916, 2011), suggesting that brain signals help regulate glucose metabolism. This regulation may require adequate insulin levels (Diabetes 60:3132, 2011). Since previous studies were performed at insulin levels ~20 µU/ml, we evaluated this regulation under […]

Read More
DiabetesLeave a Comment on 1275-OR: Central Regulation of Glucose Production Is Affected by Insulin Levels

1274-OR: Effects of Empagliflozin on Hepatic Glucose Production, Gluconeogenesis, and Lipolysis in Type 2 Diabetes

June 12, 2026 by sugaradmin

Introduction and Objective: We previously showed that SGLT2 inhibitors stimulate endogenous glucose production, offsetting their glucosuria-induced glucose lowering action, and that this effect is not explained by changes in plasma glucose, insulin, or glucagon concentration using a pancreatic clamp. To investigate the impact of Empagliflozin (an SGLT2 inhibitor) on fasting hepatic glucose production (HGP), gluconeogenic […]

Read More
DiabetesLeave a Comment on 1274-OR: Effects of Empagliflozin on Hepatic Glucose Production, Gluconeogenesis, and Lipolysis in Type 2 Diabetes

1260-OR: Fully Closed-Loop Delivery of Ultra-Rapid Insulin Lispro and Pramlintide vs. Carbohydrate Counting in Type 1 Diabetes: A Randomized, Crossover, Noninferiority Trial

June 12, 2026 by sugaradmin

Introduction and Objective: Carbohydrate counting remains a major burden in type 1 diabetes. We evaluated a novel fully closed-loop (FCL) insulin-and-pramlintide delivery system designed to eliminate carbohydrate counting.Methods: We conducted a randomized, crossover, noninferiority trial assessing 21 days of (i) hybrid closed-loop (HCL) insulin-and-placebo delivery with carbohydrate counting and FCL insulin-and-pramlintide delivery at (ii) an […]

Read More
DiabetesLeave a Comment on 1260-OR: Fully Closed-Loop Delivery of Ultra-Rapid Insulin Lispro and Pramlintide vs. Carbohydrate Counting in Type 1 Diabetes: A Randomized, Crossover, Noninferiority Trial

1240-OR: Metoclopramide Restores the Sympathoadrenal Response to Hypoglycemia in Diabetic Rats

June 12, 2026 by sugaradmin

Introduction and Objective: To investigate the potential of metoclopramide, a dopamine antagonist, in restoring impaired hypoglycemic counterregulation in a diabetic animal model.Methods: Diabetes was induced in 10-week-old Sprague-Dawley rats with streptozotocin (STZ, 65 mg/kg IP). Rats were randomized into three groups: 1) diabetic controls treated with recurrent saline (DRS, n=6), 2) diabetic rats preconditioned with […]

Read More
DiabetesLeave a Comment on 1240-OR: Metoclopramide Restores the Sympathoadrenal Response to Hypoglycemia in Diabetic Rats

Posts navigation

Older posts
Newer posts

Recent Posts

  • Could Walking Faster Help You Live Longer? Study Offers Clues
  • Menopause: How GLP-1s and Hormone Therapy Can Affect Weight Loss
  • Management of dysglycemia in critically ill adults: current evidence, clinical practice and future directions
  • What's Next—Amylin-based Therapies
  • After GLP-1s Quit Working, He Lost 80 Pounds with a Simple Procedure

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness